[
    {
        "data": {
            "description": "Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA). Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials. Both small molecule and protein therapeutics will be addressed.",
            "id": "PHMSCI 763",
            "parent": "PHMSCI",
            "title": "THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA"
        }
    },
    {
        "data": {
            "id": "PHMSCI",
            "type": "compound"
        }
    }
]